Sangamo BioSciences, Inc. To Present At Two Upcoming Investor Conferences
RICHMOND, Calif., May 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today that it will present at two upcoming investor conferences.
Rodman & Renshaw 3rd Annual Global Healthcare Conference
Sangamo will present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco. The presentation will be broadcast live over the internet on Tuesday, May 16, 2006 at 4:10 a.m. Eastern Time.
GARP Research Corporation 3rd Annual Investors Conference
Sangamo will also present at the GARP Research Corporation 3rd Annual Investors Conference in Baltimore, Maryland on Thursday, May 18 at 11:00 a.m. Eastern Time.
Both presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IRHome. The presentations will be archived on the Sangamo website for two weeks after the event.
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on macular degeneration, ischemic heart disease, congestive heart failure, neuropathic pain, and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as sickle cell anemia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, applications of Sangamo's ZFP TF technology platform and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of the ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.Sangamo BioSciences, Inc.
CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc.,+1-510-970-6000, ext. 271, or firstname.lastname@example.org; or media, Justin Jacksonof Burns McClellan, Inc., +1-212-213-0006, or email@example.com, forSangamo BioSciences, Inc.
Web site: http://www.sangamo.com//